NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$13.76

13 Sep
2024

0.150

OPEN

$13.60

1.10%

HIGH

$14.00

365,429

LOW

$13.51

TARGET
$25.00 81.7% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 123.6 56.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% - 54.4% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 24.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx123.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx231.9 M
Book Value Per Share xxxxxxxxxxxxxxx161.2
Net Operating Cash Flow xxxxxxxxxxxxxxx184.9 M
Net Profit Margin xxxxxxxxxxxxxxx67.73 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx127.30 %
Return on Invested Capital xxxxxxxxxxxxxxx127.30 %
Return on Assets xxxxxxxxxxxxxxx107.87 %
Return on Equity xxxxxxxxxxxxxxx127.30 %
Return on Total Capital xxxxxxxxxxxxxxx161.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx184.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx229 M
Price To Book Value xxxxxxxxxxxxxxx15.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.02 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx33 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/08/2024

1

Buy

$25.00

81.69%

Neuren Pharmaceuticals pre-released 1H24 revenues with royalties from Daybue being the main contributor. 

Bell Potter notes operating expenses in 1H24 results were higher than expected due to R&D expenses with net profit slightly above forecasts.

The broker believes Daybue's royalties are a "lucrative" earner for the company when it is investing R&D in its second asset, NNZ-2591 which is currently in phase 3 clinical trials.

Bell Potter makes minor adjustments to earnings forecasts.

The $25 target is unchanged. Buy rating remains.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 56.40 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 65.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

08/08/2024

1

Overweight

-

-

Wilsons places the target price for Neuren Pharmaceuticals under review post the company's US licensee Acadia Pharmaceuticals reporting 2Q2024 Daybue sales which were essentially in line with the broker's expectations.

Overweight rating unchanged.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 50.60 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 32.10 cents.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
FNArena Corporate Results Monitor – 28-08-2024

Aug 28 2024 - Australia
2
Australian Broker Call *Extra* Edition – Aug 20, 2024

Aug 20 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 15, 2024

Aug 15 2024 - Daily Market Reports
4
Rudi’s View: Model Portfolios, Best Ideas & Conviction Calls

Aug 15 2024 - Rudi's View
5
Australian Broker Call *Extra* Edition – Aug 08, 2024

Aug 08 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps